- Home
- NRXS
NRXS
Neuraxis Inc.
as 04-01-2025 4:00pm EST
Stocks
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CARMEL |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 21.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.99 - $3.78 | Next Earning Date: | 03-20-2025 |
| Revenue: | $2,685,925 | Revenue Growth: | 9.18% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Neuraxis Inc. News
NRXS Breaking Stock News: Dive into NRXS Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
GlobeNewswire
13 days ago
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
GlobeNewswire
21 days ago
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
GlobeNewswire
2 months ago
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
GlobeNewswire
2 months ago
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
GlobeNewswire
3 months ago
NeurAxis Inc. Issues Letter to Shareholders
GlobeNewswire
3 months ago
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
GlobeNewswire
3 months ago
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Compare NRXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRXS Neuraxis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.